Jim Cramer Details How Eli Lilly Could Defeat Competitors

Eli Lilly and Company (NYSE:LLY) was among  Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer mentioned the stock while discussing the woes of the healthcare industry, as he said:

Next worst is healthcare. Oh, this group has just been annihilated. I’ve never seen it trading this bad ever. There are myriad problems. Federal government’s been putting pressure on drug pricing. The FDA is not exactly friendly. Investors are worried about competition, especially for the GLP-1 formulations. Now, it’s easy for me to suggest you Eli Lilly as it has multiple versions of GLP-1 drugs including a new one that may be the first that sheds fat without muscle…

Notice this version has not been approved for any of these things. But I think that if approved, it’ll ultimately give Lilly the unassailable knockout punch against Novo Nordisk because it’s got fat busting without muscle crunching. The worry I have with this one, though, it’s the same unreliable fellow shareholders who own… tech also own Lilly.

Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic conditions.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1